Tao Wang

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Year:

2026

Year:

2026

The origin of cancer is poorly understood because premalignant cells are rarely followed in their native environments. Although the spatial compartmentalization of metabolic functions is critical for proper liver function, it is unknown whether cancers arise from some zones but not others and whether there are metabolic determinants of cancer risk. Zone-specific, mosaic introduction of Ctnnb1 (catenin beta 1) and Arid2 (AT-rich interaction domain 2) mutations, commonly co-mutated genes in hepatocellular carcinoma (HCC), in mouse models showed that position and metabolic context determine clone fates. Ctnnb1 / Arid2 -driven cancers were much more likely to arise in zone 3. The zone 3 genes Gstm2 and Gstm3 were required for efficient HCC initiation, in part through inhibition of ferroptosis. In the liver, the zonal determinants of HCC development can reveal metabolic vulnerabilities of cancer.

Year:

2025

Background Spatially resolved profiling technologies to quantify transcriptomes, epigenomes, and proteomes have been emerging as groundbreaking methods for comprehensive molecular characterizations. Dimensionality reduction and visualization is an essential step to analyze and interpret spatially resolved profiling data. However, state-of-the-art dimensionality reduction methods for single-cell sequencing data, such as the t-distributed stochastic neighbor embedding (t-SNE) and uniform manifold approximation and projection (UMAP), were not tailored for spatially resolved profiling data. Results Here we developed a spatially resolved t-SNE (SpaSNE) method to integrate both spatial and molecular information. We applied it to a variety of public spatially resolved profiling datasets that were generated from 3 experimental platforms and consisted of cells from different diseases, tissues, and cell types. To compare the performances of SpaSNE, t-SNE, and UMAP, we applied them to 4 spatially resolved profiling datasets obtained from 3 distinct experimental platforms (Visium, STARmap, and MERFISH) on both diseased and normal tissues. Comparisons between SpaSNE and these state-of-the-art approaches reveal that SpaSNE achieves more accurate and meaningful visualization that better elucidates the underlying spatial and molecular data structures. Conclusions This work demonstrates the broad application of SpaSNE for reliable and robust interpretation of cell types based on both molecular and spatial information, which can set the foundation for many subsequent analysis steps, such as differential gene expression and trajectory or pseudotime analysis on the spatially resolved profiling data.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.

Year:

2024

Cancer cells exhibit phenotypical plasticity and epigenetic reprogramming that allows them to evade lineage-dependent targeted treatments by adopting lineage plasticity. The underlying mechanisms by which cancer cells exploit the epigenetic regulatory machinery to acquire lineage plasticity and therapy resistance remain poorly understood. We identified zinc finger protein 397 (ZNF397) as a bona fide coactivator of the androgen receptor (AR), essential for the transcriptional program governing AR-driven luminal lineage. ZNF397 deficiency facilitates the transition of cancer cell from an AR-driven luminal lineage to a ten-eleven translocation 2 (TET2)-driven lineage plastic state, ultimately promoting resistance to therapies inhibiting AR signaling. Intriguingly, our findings indicate that a TET2 inhibitor can eliminate the resistance to AR-targeted therapies in ZNF397-deficient tumors. These insights uncover a novel mechanism through which prostate cancer acquires lineage plasticity via epigenetic rewiring and offer promising implications for clinical interventions designed to overcome therapy resistance dictated by lineage plasticity. Significance: This study reveals a bifurcated role of ZNF397, and a TET2–driven epigenetic mechanism regulating tumor lineage plasticity and therapy response in prostate cancer, enhances the understanding of drug resistance, and unveils a new therapeutic strategy for overcoming androgen receptor-targeted therapy resistance.

Year:

2024

Figure S1. ZNF397-deficiency has bifurcated effects on PCa with or without AR inhibition. Figure S2. The impact of ZNF397-deficiency on AR protein and AR cistrome. Figure S3. ZNF397 is required for the activation of canonical AR transcriptional program. Figure S4. ZNF397-KO impairs DHT-induced AR signaling activation. Figure S5. ZNF397-KO promotes multilineage and lineage plastic gene expression. Figure S6. ZNF397-KO promotes stem-like and EMT-like transcriptional programs. Figure S7. ZNF397-KO led to induction of TET2 downstream genes. Figure S8. ZNF397-KO promotes transcriptional activation of TET2 downstream genes. Figure S9. ZNF397-deficiency has bifurcated effects on AR-dependent vs AR-independent PCas. Figure S10. Targeting TET2-driven epigenetic rewiring to overcome resistance.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (32)

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yujin Hoshida

University of Texas Southwestern Medical Center

UNITED STATES
View details

housheng hansen he

Senior Scientist

-

CANADA
View details

Zhao Wang

Associate Professor (Tenured)

Baylor College of Medicine

UNITED STATES
View details

Ariella Hanker

Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Lauren A. Byers

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ping Mu

Associate Professor

Yale University

UNITED STATES
View details

Xiaoling Li

ARS

Yale University

UNITED STATES
View details

Su Deng

Assistant Professor

Yale University

UNITED STATES
View details

Hong Zhu

-

UNITED STATES
View details

Xiaowei Zhan

University of Texas Southwestern Medical Center

UNITED STATES
View details

Shijia Zhu

Assistant Professor

University of Minnesota

UNITED STATES
View details

Jian Hu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lin Xu

Assistant Professor (tenure track)

University of Texas Southwestern Medical School

UNITED STATES
View details

Chao Cheng

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Kaiwen Wang

Assistant Professor of Data Science

Davidson College

UNITED STATES
View details

Ganesh Raj

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Guanghui Zhu

Assoicate professor

Sichuan University

CHINA
View details

Jian Qiao

University of Texas Southwestern Medical Center

UNITED STATES
View details

Purva Gopal

University of Texas Southwestern Medical Center

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Han Liang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexandre Reuben

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Carlos L. Arteaga

University of Texas Southwestern Medical Center

UNITED STATES
View details

Hao Zhu

Associate Professor

-

UNITED STATES
View details

Yitao Tang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jia Wu

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jason Guo

University of Texas Southwestern Medical Center

UNITED STATES
View details

Yunguan Wang

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Guanghua Xiao

-

UNITED STATES
View details